WO2026074164A1 - Méthodes et compositions pour le traitement du cancer - Google Patents

Méthodes et compositions pour le traitement du cancer

Info

Publication number
WO2026074164A1
WO2026074164A1 PCT/EP2025/078527 EP2025078527W WO2026074164A1 WO 2026074164 A1 WO2026074164 A1 WO 2026074164A1 EP 2025078527 W EP2025078527 W EP 2025078527W WO 2026074164 A1 WO2026074164 A1 WO 2026074164A1
Authority
WO
WIPO (PCT)
Prior art keywords
ildr
composition
christensenella
patient
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/078527
Other languages
English (en)
Inventor
Laurence Zitvogel
Jianzhou Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Saclay
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Saclay filed Critical Institut Gustave Roussy (IGR)
Publication of WO2026074164A1 publication Critical patent/WO2026074164A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention consiste à combiner une irradiation intestinale à faible dose (ILDR) avec une immunothérapie ou d'autres traitements antinéoplasiques, dans le contexte idéal d'une présence ou d'une prévalence intestinale de membres de la famille des Christensenellaceae, en particulier pour les cancers solides à un stade avancé (réfractaires à une chimiothérapie ou une immunothérapie de première ligne). L'invention concerne également une composition bactérienne, par exemple comprenant des bactéries Christensenella, destinée à être utilisée dans le traitement du cancer chez un patient, en combinaison avec une radiothérapie intestinale à faible dose (ILDR) et un traitement antinéoplasique.
PCT/EP2025/078527 2024-10-03 2025-10-03 Méthodes et compositions pour le traitement du cancer Pending WO2026074164A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP24306623 2024-10-03
EP24306623.0 2024-10-03
EP25305499.3 2025-04-04
EP25305499 2025-04-04

Publications (1)

Publication Number Publication Date
WO2026074164A1 true WO2026074164A1 (fr) 2026-04-09

Family

ID=97445599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/078527 Pending WO2026074164A1 (fr) 2024-10-03 2025-10-03 Méthodes et compositions pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2026074164A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115519A1 (fr) * 2016-12-22 2018-06-28 Institut Gustave Roussy Composition de microbiote, à titre de marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour améliorer l'efficacité d'un traitement à base d'anticorps anti-pd1/pd-l1/pd-l2
WO2020106983A1 (fr) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Procédés et compositions pour le traitement du cancer
WO2024094817A1 (fr) 2022-11-04 2024-05-10 Institut Gustave Roussy Score prédictif de résultat d'immunothérapie anticancéreuse basé sur l'analyse écologique du microbiote intestinal
WO2024140860A1 (fr) * 2022-12-27 2024-07-04 慕恩（广州）生物科技有限公司 Utilisation de christensenella sp. ou d'une composition la comprenant dans la prévention ou le traitement de tumeurs, et médicament la comprenant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115519A1 (fr) * 2016-12-22 2018-06-28 Institut Gustave Roussy Composition de microbiote, à titre de marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour améliorer l'efficacité d'un traitement à base d'anticorps anti-pd1/pd-l1/pd-l2
WO2020106983A1 (fr) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Procédés et compositions pour le traitement du cancer
WO2024094817A1 (fr) 2022-11-04 2024-05-10 Institut Gustave Roussy Score prédictif de résultat d'immunothérapie anticancéreuse basé sur l'analyse écologique du microbiote intestinal
WO2024140860A1 (fr) * 2022-12-27 2024-07-04 慕恩（广州）生物科技有限公司 Utilisation de christensenella sp. ou d'une composition la comprenant dans la prévention ou le traitement de tumeurs, et médicament la comprenant

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
BEGHINI, F.MCLVER, L.J.BLANCO-MIGUEZ, A.DUBOIS, L.ASNICAR, F.MAHARJAN, S.MAILYAN, A.MANGHI, P.SCHOLZ, M.THOMAS, A.M. ET AL., INTEGRATING TAXONOMIC, FUNCTIONAL, AND STRAIN-LEVEL PROFILING OF DIVERSE MICROBIAL COMMUNITIES WITH BIOBAKERY, vol. 3, 2021
BLANCO-MIGUEZ, A.BEGHINI, F.CUMBO, F.MCLVER, L.J.THOMPSON, K.N.ZOLFO, M.MANGHI, P.DUBOIS, L.HUANG, K.D.THOMAS, A.M. ET AL.: "Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4", NAT BIOTECHNOL, vol. 41, 2023, pages 1633 - 1644, XP093285092, DOI: 10.1038/s41587-023-01688-w
BUQUE, A.BLOY, N.PEREZ-LANZON, M.IRIBARREN, K.HUMEAU, J.POL, J.G.LEVESQUE, S.MONDRAGON, L.YAMAZAKI, T.SATO, A. ET AL.: "Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer", NAT COMMUN, vol. 11, 2020, pages 3819
CALLAHAN, B.J., MCMURDIE, P.J., ROSEN, M.J., HAN, A.W., JOHNSON, A.J., AND HOLMES, S.P.: "DADA2: High-resolution sample inference from Illumina amplicon data", NAT METHODS, vol. 13, 2016, pages 581 - 583, XP093249850, DOI: 10.1038/nmeth.3869
CHEN JIANZHOU ET AL: "Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients", CANCER CELL, CELL PRESS, US, vol. 43, no. 3, 10 March 2025 (2025-03-10), pages 361, XP087723405, ISSN: 1535-6108, [retrieved on 20250310], DOI: 10.1016/J.CCELL.2025.02.010 *
CHEN JLEVY ATIAN ALHUANG XCAI GFIDELLE MRAUBER CLY PPIZZATO ESITTERLE L: "Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients", CANCER CELL, vol. 43, no. 3, 2025, pages 361 - 379, XP087723405, DOI: 10.1016/j.ccell.2025.02.010
COLBERT, L.E.EL ALAM, M.B.WANG, R.KARPINETS, T.LO, D.LYNN, E.J.HARRIS, T.A.ELNAGGAR, J.H.YOSHIDA-COURT, K.TOMASIC, K. ET AL.: "Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring", CANCER CELL, vol. 41, 2023, pages 1945 - 1962
DEROSA, L.ROUTY, B.DESILETS, A.DAILLERE, R.TERRISSE, S.KROEMER, G.ZITVOGEL, L.: "Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?", CANCER DISCOV, vol. 11, 2021, pages 2396 - 2412, XP055925491, DOI: 10.1158/2159-8290.CD-21-0236
DURAND, S.GRAJEDA-IGLESIAS, C.APRAHAMIAN, F.NIRMALATHASAN, N.KEPP, O.KROEMER, G.: "The intracellular metabolome of starving cells", METHODS CELL BIOL, vol. 164, 2021, pages 137 - 156
FERNANDES, A.OLIVEIRA, A.SOARES, R.BARATA, P.: "The Effects of Ionizing Radiation on Gut Microbiota, a Systematic Review", NUTRIENTS, vol. 13, 2021
FERNANDES, A.OLIVEIRA, A.SOARES, R.BARATA, P: "The Effects of Ionizing Radiation on Gut Microbiota: What Can Animal Models Tell Us?-A Systematic Review", CURR ISSUES MOL BIOL, vol. 45, 2023, pages 3877 - 3910
FIDELLE, M.RAUBER, C.ALVES COSTA SILVA, C.TIAN, A.L.LAHMAR, I.DE LA VARENDEA.M., ZHAO, L.THELEMAQUE, C.LEBHAR, I.MESSAOUDENE, M. E: "A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers", SCIENCE, vol. 380, 2023, pages 2296
FLUCKIGER, A.DAILLERE, R.SASSI, M.SIXT, B.S.LIU, P.LOOS, F.RICHARD, C.RABU, C.ALOU, M.T.GOUBET, A.G. ET AL.: "Cross-reactivity between tumor MHC class I- restricted antigens and an enterococcal bacteriophage", SCIENCE, vol. 369, 2020, pages 936 - 942
GOPALAKRISHNAN, V.SPENCER, C.N.NEZI, L.REUBEN, A.ANDREWS, M.C.KARPINETS, T.V.PRIETO, P.A.VICENTE, D.HOFFMAN, K.WEI, S.C. ET AL.: "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients", SCIENCE, vol. 359, 2018, pages 97 - 103, XP055554925, DOI: 10.1126/science.aan4236
GRAJEDA-IGLESIAS, C.DURAND, S.DAILLERE, R.IRIBARREN, K.LEMAITRE, F.DEROSA, L.APRAHAMIAN, F.BOSSUT, N.NIRMALATHASAN, N.MADEO, F. ET: "Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites", AGING, vol. 13, 2021, pages 6375 - 6405
GUO, H.CHOU, W.C.LAI, Y.LIANG, K.TAM, J.W.BRICKEY, W.J.CHEN, L.MONTGOMERY, N.D.LI, X.BOHANNON, L.M. ET AL.: "Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites", SCIENCE, vol. 370, 2020
HAUER-JENSEN, M.DENHAM, J.W.ANDREYEV, H.J.: "Radiation enteropathy-pathogenesis, treatment and prevention", NAT REV GASTROENTEROL HEPATOL, vol. 11, 2014, pages 470 - 479, XP055640559, DOI: 10.1038/nrgastro.2014.46
JADON, R.HIGGINS, E.HANNA, L.EVANS, M.COLES, B.STAFFURTH, J.: "A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy", RADIAT ONCOL, vol. 14, 2019, pages 57
LIU, X.ZHOU, Y.WANG, S.GUAN, H.HU, S.HUANG, R.ZHOU, P.: "Impact of Low-Dose Ionizing Radiation on the Composition of the Gut Microbiota of Mice", TOXICOL SCI, vol. 171, 2019, pages 258 - 268
MA, S.SHUNGIN, D.MALLICK, H.SCHIRMER, M.NGUYEN, L.H.KOLDE, R.FRANZOSA, E.VLAMAKIS, H.XAVIER, R.HUTTENHOWER, C.: "Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin", GENOME BIOL, vol. 23, 2022, pages 208
MINN, A.J.WHERRY, E.J.: "Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling", CELL, vol. 165, 2016, pages 272 - 275, XP029496640, DOI: 10.1016/j.cell.2016.03.031
MORAD, G.HELMINK, B.A.SHARMA, P.WARGO, J.A.: "Hallmarks of response, resistance, and toxicity to immune checkpoint blockade", CELL, vol. 185, 2022, pages 576
PASOLLI, E.SCHIFFER, L.MANGHI, P.RENSON, A.OBENCHAIN, V.TRUONG, D.T.BEGHINI, F.MALIK, F.RAMOS, M.DOWD, J.B. ET AL.: "Accessible, curated metagenomic data through ExperimentHub", NAT METHODS, vol. 14, 2017, pages 1023 - 1024
PITT, J.M.VETIZOU, M.DAILLERE, R.ROBERTI, M.P.YAMAZAKI, T.ROUTY, B.LEPAGE, P.BONECA, I.G.CHAMAILLARD, M.KROEMER, G.: "Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors", IMMUNITY, vol. 44, 2016, pages 1255 - 1269, XP029619117, DOI: 10.1016/j.immuni.2016.06.001
RIBAS, A.WOLCHOK, J.D.: "Cancer immunotherapy using checkpoint blockade", SCIENCE, vol. 359, 2018, pages 1350 - 1355, XP055537294, DOI: 10.1126/science.aar4060
RICHTER, C., THIEME, S., BANDOLA, J., LAUGSCH, M., ANASTASSIADIS, K., AND BRENNER, S.: "Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo", PLOS ONE, vol. 8, 2013, pages 62621
ROBERTI, M.P.YONEKURA, S.DUONG, C.P.M.PICARD, M.FERRERE, G.TIDJANI ALOU, M.RAUBER, C.LEBBA, V.LEHMANN, C.H.K.AMON, L. ET AL.: "Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer", NAT MED, vol. 26, 2020, pages 919 - 931, XP037173406, DOI: 10.1038/s41591-020-0882-8
ROUTY, B.LE CHATELIER, E.DEROSA, L.DUONG, C.P.M.ALOU, M.T.DAILLERE, R.FLUCKIGER, A.MESSAOUDENE, M.RAUBER, C.ROBERTI, M.P. ET AL.: "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", SCIENCE, vol. 359, 2018, pages 91 - 97, XP055554928, DOI: 10.1126/science.aan3706
RUAUD, A.ESQUIVEL-ELIZONDO, S.CUESTA-ZULUAGA, J.WATERS, J.L.ANGENENT, L.T.YOUNGBLUT, N.D.LEY, R.E.: "Syntrophy via Interspecies H(2) Transfer between Christensenella and Methanobrevibacter Underlies Their Global Cooccurrence in the Human Gut", MBIO, vol. 11, 2020
TENG, H.WANG, Y.SUI, X.FAN, J.LI, S.LEI, X.SHI, C.SUN, W.SONG, M.WANG, H. ET AL.: "Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer", CANCER CELL, vol. 41, 2023, pages 124 - 138
VETIZOU, M.PITT, J.M.DAILLERE, R.LEPAGE, P.WALDSCHMITT, N.FLAMENT, C.RUSAKIEWICZ, S.ROUTY, B.ROBERTI, M.P.DUONG, C.P. ET AL.: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", SCIENCE, vol. 350, 2015, pages 1079 - 1084, XP055691620, DOI: 10.1126/science.aad1329
ZHAO, L., LIU, P., XIE, W., ZHANG, S., THIEME, S., ZITVOGEL, L., KROEMER, G., AND KEPP, O.: "A genotype-phenotype screening system using conditionally immortalized immature dendritic cells", STAR PROTOC, vol. 2, 2021, pages 100732
ZHAO, L.LIU, P.MAO, M.ZHANG, S.BIGENWALD, C.DUTERTRE, C.A.LEHMANN, C.H.K.PAN, H.PAULHAN, N.AMON, L. ET AL.: "BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance", CANCER DISCOV, vol. 10, 2023
ZITVOGEL, L.MA, Y.RAOULT, D.KROEMER, G.GAJEWSKI, T.F.: "The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies", SCIENCE, vol. 359, 2018, pages 1366 - 1370, XP055746988, DOI: 10.1126/science.aar6918

Similar Documents

Publication Publication Date Title
Chen et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Iorgulescu et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma
Uribe-Herranz et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response
Sceneay et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
Anfray et al. Intratumoral combination therapy with poly (I: C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Liu et al. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond
Rini et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
JP6662775B2 (ja) 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター（プレ、プロ又はシンバイオティクス）の使用
Oh et al. Age-related tumor growth in mice is related to integrin α 4 in CD8+ T cells
Phelps et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy
ES3010296T3 (en) Intestinal microbiota and gvhd
Shen et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
US11260083B2 (en) Compositions and methods for treating and preventing graft versus host disease
CN110582291A (zh) 抗pd1/pd-l1/pd-l2抗体的反应性标志物和功效改善用调节剂
KR20190085000A (ko) 면역억제성 간엽 세포 및 그것의 형성 방법
Kim et al. Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation
CN110799201A (zh) 用于使nk细胞活化的组合物和方法
Yan et al. Ligilactobacillus salivarius CCFM 1266 modulates gut microbiota and GPR109a-mediated immune suppression to attenuate immune checkpoint blockade-induced colitis
Liu et al. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
JP7040701B2 (ja) 抗がん腫瘍溶解性ウイルス併用療法および優良レスポンダー選択プラットフォーム
US20250268958A1 (en) Commensal bacteria promote endocrine-resistance in prostate cancer via androgen biosynthesis
JP6764790B2 (ja) 視神経脊髄炎の治療に対する高可溶性アクアポリン−４細胞外ループペプチド免疫化
Chen et al. Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations
WO2026074164A1 (fr) Méthodes et compositions pour le traitement du cancer
EP4608970A2 (fr) Cellules pd-1+cd38hicd8+t et utilisations associées